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Abstract
Background: Herpes simplex virus (HSV) is frequently detected in the respiratory tract of mechanically ventilated
patients. The aim of this study was to assess current evidence to determine whether antiviral therapy is associated
with better outcomes in these patients.
Methods: MEDLINE, ISI Web of Science, Cochrane Database and ClinicalTrials.gov were searched from inception to 25
May 2020. All clinical studies investigating the effects of antiviral therapy on the outcome of mechanically ventilated
ICU patients in whom HSV was detected in the respiratory tract were eligible for inclusion, regardless of study design,
publication status or language. Titles and abstracts were reviewed independently by two authors. If the articles seemed
eligible, full-text articles were reviewed and data extracted.
We performed a random-effects meta-analysis to estimate relative risks (RRs) with corresponding 95% confidence
intervals (CIs). The primary endpoint was hospital all-cause mortality.
Results: Nine studies were included in the meta-analysis (one randomized controlled trial, eight cohort studies).
Antiviral treatment was associated with lower hospital mortality (with antiviral treatment, 40.6% (189 out of 465
patients); without, 52.7% (193 out of 366 patients); RR 0.74 [0.64, 0.85]; eight studies, low quality of evidence).
Furthermore, antiviral treatment was associated with lower 30-day mortality (RR 0.75 [0.59, 0.94]; three studies, very low
quality of evidence). We did not observe evidence for differences in ICU mortality (RR 0.73 [0.51, 1.05]; three studies,
very low quality of evidence).
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Conclusions: This meta-analysis of the available data shows that antiviral therapy might result in lower hospital and
30-day all-cause mortality in mechanically ventilated ICU patients who are positive for HSV in the respiratory tract.
However, this result must be interpreted with great caution due to the high risk of bias and limited number of patients.
Large, well-designed randomized controlled clinical trials are urgently needed.
Trial registration: The study was registered in advance on International Prospective Register of Systematic Reviews
(CRD42020180053).
Keywords: Herpes simplex, Mechanical ventilation, Antiviral therapy, Critically ill
Introduction
Herpes simplex virus (HSV) causes a variety of infections
that affect mucocutaneous surfaces, the central nervous
system and, occasionally, visceral organs. After primary in-
fection, HSV invades neurons and subsequently remains
in a non-replicating form in the sensory ganglia for the
entire lifespan of the infected individual [1]. During the la-
tency period, reactivation of the infection can be triggered
by a wide range of stimuli, including local (e.g. tissue le-
sions or UV light) or systemic stimuli (e.g. fever, impair-
ment of the immune system during critical illness or
surgery) [1]. Oropharyngeal HSV reactivation has been
shown to occur in 20 to 54% of critically ill patients, de-
pending on the study population and the severity of dis-
ease [2–6]. In patients with prolonged mechanical
ventilation, HSV can be detected in the bronchoalveolar
lavage (BAL) in up to 64% of patients in intensive care
units (ICUs) [7]. However, whether antiviral therapy im-
proves patients’ outcomes in these circumstances is a mat-
ter of debate [8, 9]. It remains unclear whether the
detection of HSV represents harmless viral shedding as a
consequence of reactivation, reflecting the severity of the
underlying disease and/or a surrogate for a state of de-
creased virological immune response (immunoparalysis),
or a true clinical infection requiring antiviral therapy [9–
11]. Study results are conflicting. Mortality in patients
with HSV in respiratory secretions was increased in some
[6, 12–14] but not in other studies [5, 7, 15]. The decision
is further complicated by the challenge of rendering a
confident clinical diagnosis of HSV bronchopulmonary in-
fection in these patients [16]. The aim of the present sys-
tematic review and meta-analysis is to assess the current
evidence as to whether antiviral therapy is associated with
better outcomes in mechanically ventilated ICU patients
in whom HSV was detected in the respiratory tract.
Material and methods
The systematic review and meta-analysis were per-
formed according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) and
Meta-Analysis of Observational Studies in Epidemiology
(MOOSE) guidelines. Complete details, including elec-
tronic search strategy, objectives, criteria for study
selection, eligibility, data collection and assessment of
study quality, were registered in advance in the PROS-
PERO International Prospective Register of Systematic
Reviews (CRD42020180053).
Literature search and data extraction
All clinical studies investigating the effects of antiviral
therapy on the outcome of mechanically ventilated ICU
patients in whom HSV was detected in the respiratory
tract were eligible for inclusion, regardless of study de-
sign, publication status or language. Information on our
primary outcome (in-hospital all-cause mortality) and
our secondary outcomes (30-day all-cause mortality,
ICU all-cause mortality) must have been reported. There
was no minimal number of patients. There were no min-
imal numbers of exclusion criteria. We searched MEDL
INE, ISI Web of Science (Science Citation Index Ex-
panded), Cochrane Database and ClinicalTrials.gov from
inception to 25 May 2020 for eligible clinical studies.
The search terms are provided (Supplementary Table 1).
We complemented the database searches by screening
the reference lists of relevant studies and reviews as well
as by directly asking selected experts for studies that
they were aware of but were not already included in this
analysis. Two authors (S.W., S.H.) independently per-
formed the literature search, identified all studies poten-
tially relevant for this review and selected studies that
were included. Conflicts over inclusion were resolved
through consensus. All study authors were contacted in
order to retrieve all additional available data (including
information on missing data).
Data extraction and risk of bias assessment
One author (S.H.) extracted the number of patients and
events for both treatment groups (with or without anti-
viral therapy). A second author (S.W.) independently vali-
dated the results. One study [17] reported mortality;
however, it did not specify the timepoint. We decided to
include this article and classified it as hospital all-cause
mortality. To assess potential heterogeneity of the study
populations, we extracted information on study designs
and settings as well as summarized patient characteristics.
Two authors (S.W. and S.H.) independently performed a
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formal risk assessment of the individual studies according
to the Newcastle-Ottawa Scale (NOS) (Supplementary
Table 2) [18]. Differences in judgement were resolved by
discussion. The certainty of evidence of the individual
studies was judged according to the guidelines of the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) working group [19, 20].
Synthesis of results
We applied random-effects meta-analyses to estimate
relative risks (RRs) for the primary and secondary end-
points. Studies were pooled according to the Mantel-
Haenszel and DerSimonian-Laird methods for within-
study and between-study variance, respectively [21–23].
We applied a continuity correction of 0.5 in studies with
cell frequencies of zero. Statistical heterogeneity was
evaluated by the I2 statistic. Heterogeneity was judged
accordingly: 0 to 40% = low, 30 to 60% =moderate, 50 to
90% = substantial (or high) and 75 to 100% = consider-
able. The importance of this measure depends on the
magnitude and direction of effects as well as the preci-
sion of the estimate (often judged by the corresponding
p value from the chi-squared test) [24]. To identify po-
tential evidence of publication bias, we additionally
inspected funnel plots. For the sensitivity analyses, we (i)
performed the meta-analysis with odds ratios (ORs) as a
measure of effect size, (ii) applied leave-one-out cross-
validation and (iii) assumed that mortality reported in
[17] was ICU all-cause mortality. We reported point es-
timates (RR or OR) together with their corresponding
95% confidence intervals (CIs) and presented the results
as forest plots. All analyses were performed with R (ver-
sion 3.6.0; R package meta, version 4.11.0) [25].
Results
Study selection
Our database search revealed 884 reports (see Table 1,
Fig. 1). In addition, we considered one of our own stud-
ies, which was unpublished at that point [27], as well as
seven studies from other sources. We removed 145 du-
plicates. Of the remaining 747 references, 738 studies
were excluded due to lack of relevant information re-
garding our predefined outcome parameters. Finally, we
identified and analysed nine studies comprising 1069 pa-
tients who had investigated at least one of the outcome
parameters. All but one of these studies were non-
randomized cohort studies, with the majority of retro-
spective design. Among the included studies, acyclovir
was most often used for therapy. The only randomized
study was performed by Luyt et al. [28]. In this double-
blind, placebo-controlled trial, 238 patients who received
mechanical ventilation for at least 96 h and continued to
receive mechanical ventilation for at least 48 h with HSV
oropharyngeal reactivation were included. The aim of
the study was to determine whether pre-emptive treat-
ment with intravenous acyclovir reduces the duration of
mechanical ventilation in patients with HSV oropharyn-
geal reactivation. Detailed characteristics of the included
studies are provided in Table 1.
Hospital all-cause mortality
For the primary endpoint, hospital all-cause mortality,
data from eight studies comprising 831 patients were
used (Fig. 2a) [5, 7, 11, 17, 26, 27, 29, 31]. In these stud-
ies, hospital all-cause mortality was lower in patients
with antiviral therapy (40.6%, 189 out of 465 patients)
than in patients without antiviral therapy (52.7%, 193
out of 366 patients). This resulted in a RR of 0.74 [0.64,
0.85]. Heterogeneity was low in the studies reporting
hospital all-cause mortality (I2 = 0%, p = 0.43). These re-
sults were supported by the sensitivity analyses (Supple-
mentary Fig. 1A, Supplementary Table 3).
Secondary outcomes
Overall, we identified three studies [27–29] reporting 30-day
all-cause mortality in 633 patients (Fig. 2b) and four studies
[11, 27, 29, 31] reporting ICU all-cause mortality in 629 pa-
tients (Fig. 2c). Pooling these studies, antiviral treatment was
associated with lower 30-day all-cause mortality (RR 0.75
[0.59, 0.94]). However, no evidence for an association with
ICU all-cause mortality was observed (RR 0.73 [0.51, 1.05]).
Heterogeneity was low in 30-day all-cause mortality (I2 =
17%, p= 0.30) but substantial in ICU all-cause mortality
(I2 = 68%, p= 0.03). These results were in line with those of
the sensitivity analyses (Supplementary Fig. 1B and C,
Supplementary Table 3; ICU all-cause mortality including
[17]: RR 0.75 [0.57, 1.00], I2 = 56.5% with p= 0.06).
Assessment of bias
Funnel plots revealed no evidence of publication bias,
particularly for those studies reporting hospital all-cause
mortality (Supplementary Fig. 2). However, the small
number of studies reporting the secondary endpoints
hampered the assessment. According to the GRADE
classification, we judged the quality of evidence to be
low for hospital all-cause mortality and very low for the
secondary endpoints due to the inherent high risk of bias
introduced by retrospective, non-randomized trial de-
signs (Table 2). In particular, indication bias could not
be ruled out, which could possibly over- or underesti-
mate the favourable treatment effect of antiviral therapy
(i.e. patients with a higher probability of survival are
more likely to be treated and vice versa). Subcategories
of bias (such as selection, allocation, performance, attri-
tion or reporting bias) were not assessed.
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Discussion
To the best of our knowledge, this is the first systematic
review and meta-analysis aiming to summarize the current
evidence for antiviral therapy for mechanically ventilated
ICU patients in whom HSV was detected in the respira-
tory tract. Our literature search identified nine studies
with 1069 patients overall. The results of the meta-
analysis of the available data showed that antiviral therapy
might improve hospital all-cause mortality as well as 30-
day all-cause mortality in mechanically ventilated patients
in whom HSV was detected in the respiratory tract. These
results suggest that the detection of HSV in these circum-
stances is of clinical relevance, albeit most likely only in
some cases, not all. This is supported by an observation
from Luyt et al. [7]. In that retrospective study, in 32.6% of
129 patients in whom HSV was detected in the BAL, HSV
bronchopneumonitis was histologically confirmed.
However, due to its complexity and risks, a lung biopsy
for securing a diagnosis of HSV bronchopneumonitis is
not routinely feasible in critically ill patients. In addition,
cytologic changes typical for HSV infection, i.e. multinu-
cleated giant cells with specific nuclear inclusions, are ad-
mittedly specific but suffer from poor sensitivity [32]. On
the other hand, rendering a confident clinical diagnosis of
HSV bronchopulmonary infection in mechanically venti-
lated patients without lung biopsy is challenging. Clinical
symptoms of HSV bronchopneumonitis are nonspecific
and often mimic bacterial pneumonia, with fever, hypox-
emia and purulent pulmonary secretions. The same is true
for the radiologic examinations, which are often nonspe-
cific and can show ground-glass attenuations, air-space
consolidations and interlobular thickening [16].
Randomized controlled studies are necessary to iden-
tify patients who could benefit (the most) from antiviral
Fig. 1 PRISMA flow diagram of study identification and selection process for outcome analysis
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therapy and to reduce therapy-associated adverse events
in others. In addition to clinical signs of a respiratory
tract infection, possible criteria might be location of de-
tection, i.e. upper respiratory tract/oropharyngeal cavity
versus lower respiratory tract/BAL [31] and amount of
virus load [29]. For example, Traen et al. [31] retrospect-
ively analysed 212 ICU patients with a positive HSV-1
culture from the endotracheal/bronchial aspirate (n =
162) or BAL (n = 50). In their study, using propensity
score matching, acyclovir therapy was associated with
lower ICU mortality (OR 0.31, 95% CI 0.18–0.56) and
lower in-hospital mortality (OR 0.28, 95% CI 0.17–0.46).
In particular, the subgroup of patients with HSV-1 de-
tected in the BAL accounted mostly for this difference.
Most recently, in a retrospective study, Schuierer et al.
[29] investigated whether patients with ventilator-
associated pneumonia (VAP) not responding to antibi-
otics and in whom HSV could be detected in respiratory
secretions (BAL or tracheal aspirates) would benefit
from acyclovir treatment. In their cohort of 425 patients
screened for HSV type 1 or 2, 57 (13.4%) patients had a
low viral load (103–105 HSV copies/ml) and 69 (16.2%)
patients a high (> 105 HSV copies/ml) viral load. Thirty
patients (7%) with a low viral load and 59 (14%) patients
with a high viral load fulfilled the strict inclusion criteria,
i.e. VAP not responding to antibiotics, and were in-
cluded in the analyses. The authors observed in patients
with a high viral load that acyclovir therapy was associ-
ated with lower hazard rates for ICU death (treated, 20
out 49 patients died; untreated, 6 out of 10 died; hazard
ratio (HR) 0.31, 95% CI 0.11–0.92) as well as for 30-day
mortality (treated, 21 out of 49 patients died; untreated,
8 out of 10; HR 0.32, 95% CI 0.12–0.85) and resulted in
better circulatory and pulmonary oxygenation function
over the course of acyclovir treatment compared to no
acyclovir treatment [29, 30]. Thus, material from the
Fig. 2 Results for the primary and secondary endpoints in mechanically ventilated patients with HSV detection in respiratory tract. CI, confidence
interval; HSV, herpes simplex virus; ICU, intensive care unit; RR, relative risk
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lower respiratory tract and evaluation of viral load in
combination with clinical signs and high likelihood of
viral pneumonia might be helpful for identifying patients
who may benefit the most from antiviral therapy. How-
ever, the possibility of adverse events related to antiviral
therapy has also to be taken into account. Nephrotox-
icity is the most important side effect of acyclovir, with
an overall incidence of acute kidney injury (AKI) of 13%,
half of which are KDIGO grade 2/3, as recently reported
by Ryan et al. [33]. However, studies showed that
acyclovir-associated nephrotoxicity was usually revers-
ible and could be minimized by slow infusion and ad-
equate hydration [34]. Moreover, three of the studies
included in this meta-analysis reporting nephrotoxicity
did not observe a significant deterioration of renal func-
tion [27–30].
Limitations
The findings and interpretations of this meta-analysis
and systematic review are limited by the quality of avail-
able evidence. The majority of available evidence was de-
rived from non-randomized, single-centre studies with
an inherent high risk of bias. In addition, studies were
heterogeneous in terms of included and analysed study
cohorts, ranging from patients with HSV detection in
the oropharyngeal cavity only [28] to patients with histo-
logically confirmed HSV bronchopneumonitis [7]. To
account for this heterogeneity, we used random-effects
meta-analyses and performed sensitivity analyses that
supported the results of our main analyses. Finally, we
did not manually search for unpublished studies, other
than conference proceedings that are covered by the uti-
lized electronic databases. Notwithstanding these limita-
tions, the present meta-analysis provides the most
comprehensive evaluation of the evidence for antiviral
therapy for mechanically ventilated ICU patients in
whom HSV was detected in the respiratory tract.
Conclusion
HSV is frequently detected in the respiratory tract of
mechanically ventilated ICU patients. Our meta-analysis
of the available data suggests that antiviral therapy is as-
sociated with lower hospital all-cause mortality as well
as 30-day all-cause mortality. Multicentre, randomized
controlled studies are urgently required to identify pa-
tients who may benefit the most from antiviral therapy.
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